IDH1 and central nervous system cancer: In IDH-1 mutant gliomas, there is a higher NK-κB pathway activation, leading to NK cell migration in a CX3CL1-dependent manner, thus bringing a possible explanation for better outcomes observed in this setting compared to IDH-1 wild-type tumors [134].